Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates (Q36498963)

14 August 2017

1 reference

title

Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates (English)

1 reference

14 August 2017

1

Daniele Santini

1 reference

14 August 2017

7

Giuseppe Tonini

1 reference

14 August 2017

3

Bruno Vincenzi

1 reference

14 August 2017

2

Michele Caraglia

1 reference

14 August 2017

4

Ingunn Holen

1 reference

14 August 2017

5

Susanna Scarpa

1 reference

14 August 2017

Alfredo Budillon

6

1 reference

14 August 2017

1 June 2006

1 reference

Nature Clinical Practice Oncology

14 August 2017

1 reference

14 August 2017

3

1 reference

14 August 2017

6

1 reference

14 August 2017

325-338

1 reference

Targeted therapy with imatinib: hits and misses?

14 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

Are patients diagnosed with breast cancer before age 50 years ever cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Cholesterol and mevalonic acid modulation in cell metabolism and multiplication

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

A growing family of guanine nucleotide exchange factors is responsible for activation of ras-family GTPases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

A tagging-via-substrate technology for detection and proteomics of farnesylated proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Bisphosphonates: preclinical review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Bisphosphonates induce breast cancer cell death in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

The MAPK signalling pathways and colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Microarray analysis in the clinical management of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Gene expression profiling using RNA extracted from whole blood: technologies and clinical applications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Genomic and proteomic technologies for individualisation and improvement of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Laser capture microdissection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Emerging anti-cancer molecular mechanisms of aminobisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0520

7 January 2021

Identifiers

DOI

10.1038/NCPONC0520

1 reference

14 August 2017

1 reference

PubMed ID

16757970